CA1065324A - 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles - Google Patents
2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazolesInfo
- Publication number
- CA1065324A CA1065324A CA226,132A CA226132A CA1065324A CA 1065324 A CA1065324 A CA 1065324A CA 226132 A CA226132 A CA 226132A CA 1065324 A CA1065324 A CA 1065324A
- Authority
- CA
- Canada
- Prior art keywords
- phenylmethylene
- compound
- phenyl
- hexahydro
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- UREWVVFRSGFOEL-UHFFFAOYSA-N cyclohepta[c]pyrazole Chemical class C1=CC=CC=C2C=NN=C21 UREWVVFRSGFOEL-UHFFFAOYSA-N 0.000 title 1
- PZAYJNNTMOGLPX-UHFFFAOYSA-N cyclopenta[c]pyrazole Chemical class N1=NC2=CC=CC2=C1 PZAYJNNTMOGLPX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical group 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 33
- -1 hydrazine compound Chemical class 0.000 claims description 29
- 150000003891 oxalate salts Chemical class 0.000 claims description 25
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 9
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 7
- CTKKGXDAWIAYSA-UHFFFAOYSA-N 2,6-dibenzylidenecyclohexan-1-one Chemical compound O=C1C(=CC=2C=CC=CC=2)CCCC1=CC1=CC=CC=C1 CTKKGXDAWIAYSA-UHFFFAOYSA-N 0.000 claims description 6
- WTVHNPWCSPBZFF-UHFFFAOYSA-N 3-(8-benzylidene-3-phenyl-3,3a,4,5,6,7-hexahydrocyclohepta[c]pyrazol-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C=1C=CC=CC=1C1N(CCCN(C)C)N=C2C1CCCCC2=CC1=CC=CC=C1 WTVHNPWCSPBZFF-UHFFFAOYSA-N 0.000 claims description 6
- YUTKWFIHTBVNIE-UHFFFAOYSA-N 3-hydrazinyl-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCNN YUTKWFIHTBVNIE-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- ZHJNAQNCUSKTRA-UHFFFAOYSA-N 3-(7-benzylidene-3-phenyl-3a,4,5,6-tetrahydro-3h-indazol-2-yl)-n,n-diethylpropan-1-amine Chemical compound C=1C=CC=CC=1C1N(CCCN(CC)CC)N=C2C1CCCC2=CC1=CC=CC=C1 ZHJNAQNCUSKTRA-UHFFFAOYSA-N 0.000 claims description 3
- QPYNETAIAKXHTF-UHFFFAOYSA-N 3-(7-benzylidene-3-phenyl-3a,4,5,6-tetrahydro-3h-indazol-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C=1C=CC=CC=1C1N(CCCN(C)C)N=C2C1CCCC2=CC1=CC=CC=C1 QPYNETAIAKXHTF-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- CDWCNIVDIALVDN-UHFFFAOYSA-N 2,7-dibenzylidenecycloheptan-1-one Chemical compound O=C1C(=CC=2C=CC=CC=2)CCCCC1=CC1=CC=CC=C1 CDWCNIVDIALVDN-UHFFFAOYSA-N 0.000 claims description 2
- XXYDEJAJDOABCE-UHFFFAOYSA-N 2-hydrazinyl-n,n-dimethylethanamine Chemical compound CN(C)CCNN XXYDEJAJDOABCE-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 4
- NNPZGRUMFLDSMT-UHFFFAOYSA-N 2-(7-benzylidene-3-phenyl-3a,4,5,6-tetrahydro-3h-indazol-2-yl)-n,n-dimethylethanamine Chemical compound C=1C=CC=CC=1C1N(CCN(C)C)N=C2C1CCCC2=CC1=CC=CC=C1 NNPZGRUMFLDSMT-UHFFFAOYSA-N 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- CVTOCKKPVXJIJK-UHFFFAOYSA-N 2,5-dibenzylidenecyclopentan-1-one Chemical compound O=C1C(=CC=2C=CC=CC=2)CCC1=CC1=CC=CC=C1 CVTOCKKPVXJIJK-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 abstract description 5
- 150000002367 halogens Chemical group 0.000 abstract description 5
- 150000001204 N-oxides Chemical group 0.000 abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 abstract description 4
- 239000003874 central nervous system depressant Substances 0.000 abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
- WGZYVHFXLPDNDL-UHFFFAOYSA-N 4-benzoyl-2-phenylpyrazole-3-carbonitrile Chemical compound C=1C=CC=CC=1C(=O)C(=C1C#N)C=NN1C1=CC=CC=C1 WGZYVHFXLPDNDL-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102100037327 Chondrolectin Human genes 0.000 description 3
- 101000879734 Homo sapiens Chondrolectin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000003935 benzaldehydes Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- UJBOOUHRTQVGRU-UHFFFAOYSA-N 3-methylcyclohexan-1-one Chemical compound CC1CCCC(=O)C1 UJBOOUHRTQVGRU-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclo-pentanone Natural products O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 150000002689 maleic acids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- KMWHQYDMBYABKL-UHFFFAOYSA-N 1-iodohexadecane Chemical compound CCCCCCCCCCCCCCCCI KMWHQYDMBYABKL-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- ITPNKJOIQUOQPN-UHFFFAOYSA-N 2-indazol-2-ylethanamine Chemical compound C1=CC=CC2=NN(CCN)C=C21 ITPNKJOIQUOQPN-UHFFFAOYSA-N 0.000 description 1
- YXWOYHGDGSGAGA-UHFFFAOYSA-N 3-(7-benzylidene-5-methyl-3-phenyl-3a,4,5,6-tetrahydro-3h-indazol-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C(C)CC2C(C=3C=CC=CC=3)N(CCCN(C)C)N=C2C1=CC1=CC=CC=C1 YXWOYHGDGSGAGA-UHFFFAOYSA-N 0.000 description 1
- IEVRHAUJJJBXFH-UHFFFAOYSA-N 3-ethylcyclohexan-1-one Chemical compound CCC1CCCC(=O)C1 IEVRHAUJJJBXFH-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- MAUCRURSQMOFGV-UHFFFAOYSA-N 4-propylbenzaldehyde Chemical compound CCCC1=CC=C(C=O)C=C1 MAUCRURSQMOFGV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical class O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- JKAPLXAKEPFZOG-UHFFFAOYSA-N n,n-diethyl-3-hydrazinylpropan-1-amine Chemical group CCN(CC)CCCNN JKAPLXAKEPFZOG-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/683—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Abstract New compounds, useful as central nervous system depressants, have the following formula wherein X is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; R is hydrogen or lower alkyl with the proviso that only one occurrence of R may be lower alkyl;
m is an integer from 2 to 4; A is straight or branched alkylene of from 1 to 8 carbon atoms; B is -NH2, , , or
m is an integer from 2 to 4; A is straight or branched alkylene of from 1 to 8 carbon atoms; B is -NH2, , , or
Description
lO~S~ MT75 This invention relates to new compounds of the formula (I) X
~ m ~
wherein X is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; R is hydrogen or lower alkyl with the proviso that only one occurrence of R may be lower alkyl;
m is an integer from 2 to 4; A is straight or branched alkylene of from 1 to 8 carbon atoms; B is -NH2, -N \ 1 ' -N ~ 1 ~ or -N ~ 1 wherein R is lower alkyl and R is phenyl or phenyl-lower alkyl; and the acid-addition and quaternary salts and N~oxides thereofO These new com-pounds are central nervous system depressants.
The terms "lower alkyl" and "lower alkoxy" as employed herein include both straight and branched chain radicals of le88 than eight carbon atoms, preferably 1 to 3 carbon atoms, as for example, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, igopropoxy, etc. The term "phenyl-lower alkyl"
includes such lower alkyl groups attached to a phenyl with benzyl and phenethyl being preferred. The term "halogen" includes all the halogens but is preferably Cl.
The term "alkylene" as employed herein includes both straight and branched chain radicals of 1 to 8 carbon atom8, P ~ (CH2) ~ (CH2)2-, -ICH-CH2-~ -CH21CH-CH2-, etc.
The term "acid addition salts" is intended to mean salts which may be formed for the purposes of isolation, purification~ and storage, such as the oxalate salt, lO~;S3~t maleate salt, etc. and pharmaceutically acceptable salts meant for administration of the compound to a host, such as the hydrochloride, sulfate, acetate, citrate salts, etc.
The quaternary salts include those formed with alkyl halides (e.g. methyl chloride, isobutyl bromide, dodecyl chloride and cetyl iodide), benzyl halides (e.g. benzyl chloride) and dilower alkyl sulfates (e.g. dimethyl sulfate) by a conventional quaternization reaction.
The N-oxide may be formed by dissolving the free base of Formula I in a solvent inert to hydrogen peroxide, e.g., ethanol or chloroform, adding excess (on a molar basis) hydrogen peroxide, and allowing the mixture to stand at room temperature for several hours. An acid-addition salt of the N-oxide may be formed by addition of the desired acid, for example, those mentioned above.
The new compounds of formula I are prepared by reacting the appropriate cycloalkylone represented by formula (II) ~1 ?
(CHR
with a substituted benzaldehyde of formula (III) ~CHO
lO~S3~ MT75 to produce the intèrmediate of formula ~CH ~CH
C~)m The compounds of formula IV are converted to a com-pound of formula I by reaction with a hydrazine of formula (V) ~ N-N-A-B
H
in an organic solvent, preferably an alcohol of up to four carbon atoms at temperatures of from about 40C to about 120C, preferably at about the reflux temperature of the solvent, for from about 1/2 hour to about 12 hours, prefer-ably for about 4 hours.
The hydrazine of formula V is prepared by reacting a haloamine, B-A-halo, with an excess of hydrazine, H2NNH2 ' Alternatively, the compound of formula IV
can be reacted with a hydroxyalkyl hydrazine of formula (VI) \ N-N -A-OH
H H
to form the alcohol of formula (vII) ~ ~ X
il)~S3'~4 The alcohol of formula VII is reacted by heating with p-toluenesulfonyl chloride to form the tosylate of formula (VIII) ~ Cl ~TS
which in turn is treated with the amine of formula HB to form the compounds of formula I. This method is particularly useful in producing compounds of formula I where B is amino (i.e. the tosylate of formula VIII is reacted with ammonia).
Preferred are the compounds of formula I wherein X is hydrogen, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, trifluoromethyl, or halogen.
R is hydrogen or lower alkyl of 1 to 3 carbon atoms.
A is straight or branched chain alkylene of from 2 to 5 carbon atoms.
Rl is lower alkyl of 1 to 3 carbon atoms.
R2 is phenyl, benzyl, or phenethyl.
- 20 The most preferred compounds are those where X is hydrogen or Cl, especially hydrogen.
R is hydrogen or methy~, especially hydrogen.
H ~R
\ Rl or N\ 1 ~ especlally~-N(cH3)2.
( 2)2 or -(CH2)3-, especially -(CH2) The new compounds of the present invention are useful as central nervous system depressants in mice, cats, rats, dogs and other mammalian species when administered in amounts ranging from about 1.0 mg. to about 100 mg. per kg. of body weight per day. A pre-10~;5;~;~4 ferred dosage regimen for optimum results would be from about 10 mg. to about 50 mg. per kg. of body weight per day, and such dosage units are employed that a total of from about 35 mg. to about 3 g. of active ingredient in single or divided doses are administered in a 24 hour period. These compounds when administered to rats in the above stated dosages produced the following central nervous system depressant symptoms; decreased motor activity, ataxia, and decreased screen grip.
Eor these purposes a compound or mixture of compounds of formula I and their pharmaceutically acceptable acid-addition salts, quaternary salts, or N-oxides may be administered orally or parenterally in a conventional dosage form such as tablet, capsule, injectable or the like. These may be con-ventionally formulated in an oral or parenteral dosage form by compounding with a conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice.
The following examples are illustrative of the invention. All temperatures are expressed on the centigrade scale.
Example 1 3~3a~4~5~6~7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phen methylene)-2--indazole-2-propanamine~ oxalate salt a) 2~6-Bis(phenylmethylene)cyclohexanone A solution of 32.0 g~ (0.33 mole) of cyclohexanone, 70.0 g. (0.66 mole) of benzaldehyde, 200 ml. of ethanol and 20 m]. of concentrated HCl is heated and then refluxed for one hour. Crystallization from the deep red solution occurs and after cooling the crystallized 2,6-bis(phenylmethylene)-cyclohexanone is filtered and washed with cold ethanol and dried it~;S;~'~4 yielding 72.0 g.; m.p. 114-116. This material is re-crystallized from 120 ml. of DMF (dimethylformamide) yielding 56.0 g. (63%) of yellow 2,6-bis(phenylmethylene)-cyclohexanone; m.p. 114-116.
b) 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate s_ 11.0 g. (0.04 mole) of 2,6-bis(phenylmethylene)-cyclohexanone from part (a) is reacted with 4.8 g. (0.041 mole) of 3-dimethylaminopropyl hydrazine[see Nogrady et al., Can. J. Chem., 47, 2001 (1969)] in 100 ml. of methanol and refluxed for 4 hours. The residue remaining after the evaporation of the methanol is suspended in 100 ml. of methanol, layered over with 100 ml. of ether, stirred and basified with K2CO3. The layers sPparate and the aqueous phase is extracted with ether. The combined ether layers are dried (MgSO4) and the solvent is evaporated yielding 14.5 g. of oily base.
A warm solution of 14.0 g. of the oily base in 70 ml.
of MeCN is treated with a warm solution of 6.7 g. of oxalic acid in 70 ml. of MeCN. On cooling, 13.9 g (75%) of the oxalate salt gradually separates; m.p. 168-170 (dec). Crystallization from 25 ml. hot DMF-75 ml.
MeCN yields 12.5 g. (68~) of colorless 3,3a,4,5,6,7-l~exahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt; m.p. 177-179 (dec).
1()~53'~
Example 2 3a,4,5,6,7,8-Hexahydro-N,N-dimethyl-3-phenyl-8-(phenyl-methylene)-cyclohepta[c~pyrazole-2(3H)-propanamine, maleate salt a) 3a,4,5 ! 6,7 ! 8-Hexahydro-N,N-dimethyl-3-phenyl-8-(~henyl-methylene)-cyclohepta[c]pyrazole-2(3H)-propanamine, oxalate salt 8.0 g. (0.028 mole) of 2,7-bis(phenylmethylene)-cycloheptanone [See Piantadosi et al., J. Med. Chem., 16, 770 (1973)] and 3.4 g. (0.029 mole) of 3-dimethylamino-propylhydrazine are reacted in 70 ml. of methanol as des-cribed in example l(b) yielding 11.2 g. of oily base.
11.0 g. of this oily base is dissolved in 70 ml. of MeCN and treated with a warm solution of 2.8 g. of oxalic acid in 50 ml. of MeCN. On rubbing and cooling, 13 g. of the ox~late salt slowly separates; m.p. 143-145 (s. 137).
Crystallization from 25 ml. warm DMF-75 ml. MeCN yields 7.0 g. of cream colored 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta[c]pyrazole-2(3H)-propanamine, oxalate salt; m.p. 152-154.
b) 3a,4,5,6,7,8-Hexahydro-N,N-dimethyl-3-phenyl-8-(phenyl-methylene)-cyclohepta[c]pyrazole-2(3H)-propanamine The oxalate salt from part (a) is suspended in water and is basified with K2CO3 and extracted with ether yielding 5.5 g. of oily base. 5.0 g. of this oily base is crystallized from 25 ml. of MeCN yielding 4.4 g. of cream colored 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-~c]pyrazole-2(3H)-propanamine; m.p. 92-94 (s. 90).
c) 3a,4,5!6!?,8-Hexahydro-N~N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta [c]pyrazole-2(3~)-propanamine~ maleate salt, lO~S3'~
The base from part (b) and 1.3 g. of maleic acid are dissolved in 25 ml. of warm MeCN and diluted to approximately 600 ml. with ether. On rubbing and standing in the cold, the crystalline maleate salt slowly separates. After four days in the cold, the maleate salt is filtered, washed with ether, and dried in vacuo yielding 4.1 g. (32%);
m.p. 109-111. Crystallization from 25 ml. methanol-250 ml.
ether yields 3.5 g. (27%) of nearly colorless 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamine, maleate, m.p. 109-111.
Example 3 3a,4,5,6-Tetrahydro-N,N-dimethyl-3-phenyl-6-(phenylmethylene~-cyclopentapyrazole-2(3-)-propanamine~ hydrochloride This compound is prepared by following the procedure of example 1 but substituting cyclopentanone for the cyclo-hexanone to give the free base, m.p. 116-118. The hydro-ch;orid~ salt, made in the usual manner, was crystallized from acetonitrile, m.p. 167-169.
Examples 4-11 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-(substituted phenyl)-7-[(substituted-phenyl)methylene]-2H-indazole-2-propanamine, oxalate salts According to the procedure of example la, upon substituting in place of the benzaldehyde, one of the following substituted benzaldehydes:
o-chlorobenzaldehyde p-chlorobenzaldehyde p-trifluoromethylbenzaldehyde m-fluorobenzaldehyde o-methylbenzaldehyde 1()~53~ MT75 p-propylbenzaldehyde m-ethoxybenzaldehyde p-propoxybenzaldehyde one obtains the following
~ m ~
wherein X is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; R is hydrogen or lower alkyl with the proviso that only one occurrence of R may be lower alkyl;
m is an integer from 2 to 4; A is straight or branched alkylene of from 1 to 8 carbon atoms; B is -NH2, -N \ 1 ' -N ~ 1 ~ or -N ~ 1 wherein R is lower alkyl and R is phenyl or phenyl-lower alkyl; and the acid-addition and quaternary salts and N~oxides thereofO These new com-pounds are central nervous system depressants.
The terms "lower alkyl" and "lower alkoxy" as employed herein include both straight and branched chain radicals of le88 than eight carbon atoms, preferably 1 to 3 carbon atoms, as for example, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, igopropoxy, etc. The term "phenyl-lower alkyl"
includes such lower alkyl groups attached to a phenyl with benzyl and phenethyl being preferred. The term "halogen" includes all the halogens but is preferably Cl.
The term "alkylene" as employed herein includes both straight and branched chain radicals of 1 to 8 carbon atom8, P ~ (CH2) ~ (CH2)2-, -ICH-CH2-~ -CH21CH-CH2-, etc.
The term "acid addition salts" is intended to mean salts which may be formed for the purposes of isolation, purification~ and storage, such as the oxalate salt, lO~;S3~t maleate salt, etc. and pharmaceutically acceptable salts meant for administration of the compound to a host, such as the hydrochloride, sulfate, acetate, citrate salts, etc.
The quaternary salts include those formed with alkyl halides (e.g. methyl chloride, isobutyl bromide, dodecyl chloride and cetyl iodide), benzyl halides (e.g. benzyl chloride) and dilower alkyl sulfates (e.g. dimethyl sulfate) by a conventional quaternization reaction.
The N-oxide may be formed by dissolving the free base of Formula I in a solvent inert to hydrogen peroxide, e.g., ethanol or chloroform, adding excess (on a molar basis) hydrogen peroxide, and allowing the mixture to stand at room temperature for several hours. An acid-addition salt of the N-oxide may be formed by addition of the desired acid, for example, those mentioned above.
The new compounds of formula I are prepared by reacting the appropriate cycloalkylone represented by formula (II) ~1 ?
(CHR
with a substituted benzaldehyde of formula (III) ~CHO
lO~S3~ MT75 to produce the intèrmediate of formula ~CH ~CH
C~)m The compounds of formula IV are converted to a com-pound of formula I by reaction with a hydrazine of formula (V) ~ N-N-A-B
H
in an organic solvent, preferably an alcohol of up to four carbon atoms at temperatures of from about 40C to about 120C, preferably at about the reflux temperature of the solvent, for from about 1/2 hour to about 12 hours, prefer-ably for about 4 hours.
The hydrazine of formula V is prepared by reacting a haloamine, B-A-halo, with an excess of hydrazine, H2NNH2 ' Alternatively, the compound of formula IV
can be reacted with a hydroxyalkyl hydrazine of formula (VI) \ N-N -A-OH
H H
to form the alcohol of formula (vII) ~ ~ X
il)~S3'~4 The alcohol of formula VII is reacted by heating with p-toluenesulfonyl chloride to form the tosylate of formula (VIII) ~ Cl ~TS
which in turn is treated with the amine of formula HB to form the compounds of formula I. This method is particularly useful in producing compounds of formula I where B is amino (i.e. the tosylate of formula VIII is reacted with ammonia).
Preferred are the compounds of formula I wherein X is hydrogen, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, trifluoromethyl, or halogen.
R is hydrogen or lower alkyl of 1 to 3 carbon atoms.
A is straight or branched chain alkylene of from 2 to 5 carbon atoms.
Rl is lower alkyl of 1 to 3 carbon atoms.
R2 is phenyl, benzyl, or phenethyl.
- 20 The most preferred compounds are those where X is hydrogen or Cl, especially hydrogen.
R is hydrogen or methy~, especially hydrogen.
H ~R
\ Rl or N\ 1 ~ especlally~-N(cH3)2.
( 2)2 or -(CH2)3-, especially -(CH2) The new compounds of the present invention are useful as central nervous system depressants in mice, cats, rats, dogs and other mammalian species when administered in amounts ranging from about 1.0 mg. to about 100 mg. per kg. of body weight per day. A pre-10~;5;~;~4 ferred dosage regimen for optimum results would be from about 10 mg. to about 50 mg. per kg. of body weight per day, and such dosage units are employed that a total of from about 35 mg. to about 3 g. of active ingredient in single or divided doses are administered in a 24 hour period. These compounds when administered to rats in the above stated dosages produced the following central nervous system depressant symptoms; decreased motor activity, ataxia, and decreased screen grip.
Eor these purposes a compound or mixture of compounds of formula I and their pharmaceutically acceptable acid-addition salts, quaternary salts, or N-oxides may be administered orally or parenterally in a conventional dosage form such as tablet, capsule, injectable or the like. These may be con-ventionally formulated in an oral or parenteral dosage form by compounding with a conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice.
The following examples are illustrative of the invention. All temperatures are expressed on the centigrade scale.
Example 1 3~3a~4~5~6~7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phen methylene)-2--indazole-2-propanamine~ oxalate salt a) 2~6-Bis(phenylmethylene)cyclohexanone A solution of 32.0 g~ (0.33 mole) of cyclohexanone, 70.0 g. (0.66 mole) of benzaldehyde, 200 ml. of ethanol and 20 m]. of concentrated HCl is heated and then refluxed for one hour. Crystallization from the deep red solution occurs and after cooling the crystallized 2,6-bis(phenylmethylene)-cyclohexanone is filtered and washed with cold ethanol and dried it~;S;~'~4 yielding 72.0 g.; m.p. 114-116. This material is re-crystallized from 120 ml. of DMF (dimethylformamide) yielding 56.0 g. (63%) of yellow 2,6-bis(phenylmethylene)-cyclohexanone; m.p. 114-116.
b) 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate s_ 11.0 g. (0.04 mole) of 2,6-bis(phenylmethylene)-cyclohexanone from part (a) is reacted with 4.8 g. (0.041 mole) of 3-dimethylaminopropyl hydrazine[see Nogrady et al., Can. J. Chem., 47, 2001 (1969)] in 100 ml. of methanol and refluxed for 4 hours. The residue remaining after the evaporation of the methanol is suspended in 100 ml. of methanol, layered over with 100 ml. of ether, stirred and basified with K2CO3. The layers sPparate and the aqueous phase is extracted with ether. The combined ether layers are dried (MgSO4) and the solvent is evaporated yielding 14.5 g. of oily base.
A warm solution of 14.0 g. of the oily base in 70 ml.
of MeCN is treated with a warm solution of 6.7 g. of oxalic acid in 70 ml. of MeCN. On cooling, 13.9 g (75%) of the oxalate salt gradually separates; m.p. 168-170 (dec). Crystallization from 25 ml. hot DMF-75 ml.
MeCN yields 12.5 g. (68~) of colorless 3,3a,4,5,6,7-l~exahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt; m.p. 177-179 (dec).
1()~53'~
Example 2 3a,4,5,6,7,8-Hexahydro-N,N-dimethyl-3-phenyl-8-(phenyl-methylene)-cyclohepta[c~pyrazole-2(3H)-propanamine, maleate salt a) 3a,4,5 ! 6,7 ! 8-Hexahydro-N,N-dimethyl-3-phenyl-8-(~henyl-methylene)-cyclohepta[c]pyrazole-2(3H)-propanamine, oxalate salt 8.0 g. (0.028 mole) of 2,7-bis(phenylmethylene)-cycloheptanone [See Piantadosi et al., J. Med. Chem., 16, 770 (1973)] and 3.4 g. (0.029 mole) of 3-dimethylamino-propylhydrazine are reacted in 70 ml. of methanol as des-cribed in example l(b) yielding 11.2 g. of oily base.
11.0 g. of this oily base is dissolved in 70 ml. of MeCN and treated with a warm solution of 2.8 g. of oxalic acid in 50 ml. of MeCN. On rubbing and cooling, 13 g. of the ox~late salt slowly separates; m.p. 143-145 (s. 137).
Crystallization from 25 ml. warm DMF-75 ml. MeCN yields 7.0 g. of cream colored 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta[c]pyrazole-2(3H)-propanamine, oxalate salt; m.p. 152-154.
b) 3a,4,5,6,7,8-Hexahydro-N,N-dimethyl-3-phenyl-8-(phenyl-methylene)-cyclohepta[c]pyrazole-2(3H)-propanamine The oxalate salt from part (a) is suspended in water and is basified with K2CO3 and extracted with ether yielding 5.5 g. of oily base. 5.0 g. of this oily base is crystallized from 25 ml. of MeCN yielding 4.4 g. of cream colored 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-~c]pyrazole-2(3H)-propanamine; m.p. 92-94 (s. 90).
c) 3a,4,5!6!?,8-Hexahydro-N~N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta [c]pyrazole-2(3~)-propanamine~ maleate salt, lO~S3'~
The base from part (b) and 1.3 g. of maleic acid are dissolved in 25 ml. of warm MeCN and diluted to approximately 600 ml. with ether. On rubbing and standing in the cold, the crystalline maleate salt slowly separates. After four days in the cold, the maleate salt is filtered, washed with ether, and dried in vacuo yielding 4.1 g. (32%);
m.p. 109-111. Crystallization from 25 ml. methanol-250 ml.
ether yields 3.5 g. (27%) of nearly colorless 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamine, maleate, m.p. 109-111.
Example 3 3a,4,5,6-Tetrahydro-N,N-dimethyl-3-phenyl-6-(phenylmethylene~-cyclopentapyrazole-2(3-)-propanamine~ hydrochloride This compound is prepared by following the procedure of example 1 but substituting cyclopentanone for the cyclo-hexanone to give the free base, m.p. 116-118. The hydro-ch;orid~ salt, made in the usual manner, was crystallized from acetonitrile, m.p. 167-169.
Examples 4-11 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-(substituted phenyl)-7-[(substituted-phenyl)methylene]-2H-indazole-2-propanamine, oxalate salts According to the procedure of example la, upon substituting in place of the benzaldehyde, one of the following substituted benzaldehydes:
o-chlorobenzaldehyde p-chlorobenzaldehyde p-trifluoromethylbenzaldehyde m-fluorobenzaldehyde o-methylbenzaldehyde 1()~53~ MT75 p-propylbenzaldehyde m-ethoxybenzaldehyde p-propoxybenzaldehyde one obtains the following
2,6-bis[(2-chlorophenyl)methylene]cyclohexanone 2,6-bis[(4-chlorophenyl)methylene]cyclohexanone 2,6-bis[(4-trifluoromethylphenyl)methylene]cyclohexanone 2,6-bis[(3-fluorophenyl)methylen`e]cyclohexanone 2,6-bis[(2-methylphenyl)methylene]cyclohexanone 2,6-bis[(4-propylphenyl)methylene]cyclohexanone 2,6-bis[(3-ethoxyphenyl)methylene]cyclohexanone 2,6-bis[(4-propoxyphenyl)methylene]cyclohexanone Upon substituting the above compounds in example lb one obtains the following:
3,3a,4,5,6~7-hexahydro-N,N-dimethyl-3-(2-chlorophenyl)-7-[(2-chlorophenyl)methylene]-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(4-chlorophenyl)-7-[(4-chlorophenyl)methylene]-2_-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(4-trifluoromethyl-phenyl)-7-[(4-trifluoromethylphenyl)methylene]-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(3-fluorophenyl)-7-[(3-fluorophenyl)methylene]-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(2-methylphenyl)-7-[(2-methylphenyl)methylene]-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(4-propylphenyl)-7-[(4-propylphenyl)methylene]-2H-indazole-2-propanamine, _g_ 10~iS3'~4 oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-t3-ethoxyphenyl)-7-[(3-ethoxyphenyl)methylene]-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-(4-propoxyphenyl)-7-[(4-propoxyphenyl)methylene]-2H-indazole-2-propanamine, oxalate salt Similarly, the substituted benzaldehydes are employed to produce the various 2,7-bis[(substituted phenyl)methylene]-cycloheptanones and 2,5-bis[(substituted phenyl)methylene]-cyclopentanones which are reacted to produce the appropriate 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-(substituted-phenyl)-8-[(substituted-phenyl)methylene]-cyclohepta[c]pyrazole-2(3H)-propanamines and 3a,4,5,6-tetrahydro-N,N-dimethyl-3-(substituted-phenyl)-6-[(substituted-phenyl)methylene]-cyclopentapyrazole-2(3H)-propanamines.
Examples 12 to 17 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-(phenyl)-(5 or 4 and/or 6-lower alkyl)-7-(phenylmethylene)-2~-indazole-2-propanamine, oxalate salts According to the procedure of example la, upon substituting in place of the cyclohexanone, one of the following:
p-methylcyclohexanone p-ethylcyclohexanone p-propylcyclohexanone p-t-butylcyclohexanone m-methylcyclohexanone m-ethylcyclohexanone one obtains the following:
~0~
2,6-bis(phenylmethylene)(4-methylcyclohexanone) 2,6-bis(phenylmethylene)(4-ethylcyclohexanone) 2,6-bis(phenylmethylene)(4-propylcyclohexanone) 2,6-bis(phenylmethylene)(4-t-butylcyclohexanone) 2,6-bis(phenylmethylene)(3-methylcyclohexanone) 2,6-bis(phenylmethylene)(3-ethylcyclohexanone) Upon substituting the above compounds in example lb one obtains the following:
3,3a,4,5,6,7-hexahydro-N,N-dimethyl-5-methyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6 r 7-hexahydro-N,N-dimethyl-5-ethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-5-propyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-5-(t-butyl)-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt m.p. 140-143 (crystallized from isopropyl alcohol) 3,3a,4,5,6,7-hexahydro-N,~-dimethyl-(4 and/or 6-methyl)-3-phenyl 7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-(4 and/or 6-ethyl)-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt Similarly, lower alkyl substituted cycloheptanones and cyclopentanones are employed to produce the various 2,7-bis(phenylmethylene)(lower alkyl-cycloheptanones)and 2,5-bis-(phenylmethylene)(lower alkyl-cyclopentanones)which are reacted to produce the appropriate lower alkyl substituted 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamines and 3a,4,5,6-tetrahydro-N,N-dimethyl-3-phenyl-6-(phenylmethylene)-cyclopentapyrazole-2-(3H)-propanamines.
10~
Example 18 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-.
2H-indazole-2-ethanamine, oxalate salt According to the procedure of example 1 but substituting 2-dimethylaminoethyl hydrazine for the 3-dimethylaminopropyl hydrazine in example lb, the title compound is obtained; m.p.
157-159 (crystallized from ethanol-methanol). In the usual manner, this oxalate is converted to the free base and then to the maleic acid salt; m.p. 137-139 (crystallized from methanol-ether).
Example 19 3,3a,4,5,6,7-Hexahydro-N,N-diethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt According to the procedure of example 1 but substituting 3-diethylaminopropyl hydrazine for the 3-dimethylaminopropyl hydrazine in example lb, the title compound is obtained.
Crystallization from DMF (dimethylformamine)-acetonitrile gives a colorless crystalline product; m.p. 145-147. After conversion of the oxalate to the free base and then to the maleic acid salt in the usual manner, crystallization from methanol-ether gives a crystalline product which is nearly colorless; m.p. 104-106.
Examples 12 to 17 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-(phenyl)-(5 or 4 and/or 6-lower alkyl)-7-(phenylmethylene)-2~-indazole-2-propanamine, oxalate salts According to the procedure of example la, upon substituting in place of the cyclohexanone, one of the following:
p-methylcyclohexanone p-ethylcyclohexanone p-propylcyclohexanone p-t-butylcyclohexanone m-methylcyclohexanone m-ethylcyclohexanone one obtains the following:
~0~
2,6-bis(phenylmethylene)(4-methylcyclohexanone) 2,6-bis(phenylmethylene)(4-ethylcyclohexanone) 2,6-bis(phenylmethylene)(4-propylcyclohexanone) 2,6-bis(phenylmethylene)(4-t-butylcyclohexanone) 2,6-bis(phenylmethylene)(3-methylcyclohexanone) 2,6-bis(phenylmethylene)(3-ethylcyclohexanone) Upon substituting the above compounds in example lb one obtains the following:
3,3a,4,5,6,7-hexahydro-N,N-dimethyl-5-methyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6 r 7-hexahydro-N,N-dimethyl-5-ethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-5-propyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-5-(t-butyl)-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt m.p. 140-143 (crystallized from isopropyl alcohol) 3,3a,4,5,6,7-hexahydro-N,~-dimethyl-(4 and/or 6-methyl)-3-phenyl 7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-(4 and/or 6-ethyl)-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt Similarly, lower alkyl substituted cycloheptanones and cyclopentanones are employed to produce the various 2,7-bis(phenylmethylene)(lower alkyl-cycloheptanones)and 2,5-bis-(phenylmethylene)(lower alkyl-cyclopentanones)which are reacted to produce the appropriate lower alkyl substituted 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamines and 3a,4,5,6-tetrahydro-N,N-dimethyl-3-phenyl-6-(phenylmethylene)-cyclopentapyrazole-2-(3H)-propanamines.
10~
Example 18 3,3a,4,5,6,7-Hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-.
2H-indazole-2-ethanamine, oxalate salt According to the procedure of example 1 but substituting 2-dimethylaminoethyl hydrazine for the 3-dimethylaminopropyl hydrazine in example lb, the title compound is obtained; m.p.
157-159 (crystallized from ethanol-methanol). In the usual manner, this oxalate is converted to the free base and then to the maleic acid salt; m.p. 137-139 (crystallized from methanol-ether).
Example 19 3,3a,4,5,6,7-Hexahydro-N,N-diethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt According to the procedure of example 1 but substituting 3-diethylaminopropyl hydrazine for the 3-dimethylaminopropyl hydrazine in example lb, the title compound is obtained.
Crystallization from DMF (dimethylformamine)-acetonitrile gives a colorless crystalline product; m.p. 145-147. After conversion of the oxalate to the free base and then to the maleic acid salt in the usual manner, crystallization from methanol-ether gives a crystalline product which is nearly colorless; m.p. 104-106.
Claims (28)
1. A process for preparing a compound of the formula wherein R is hydrogen or lower alkyl with the proviso that only one occurrence of R may be lower alkyl; m is an integer from 2 to 4; A is straight or branched alkylene of from 2 to 5 carbon atoms; B is -NH2, or , wherein R1 is lower alkyl;
or an acid-addition salt thereof, which comprises reacting a compound of the formula with a hydrazine compound of the formula to produce the final compound, and optionally converting to an acid-addition salt thereof.
or an acid-addition salt thereof, which comprises reacting a compound of the formula with a hydrazine compound of the formula to produce the final compound, and optionally converting to an acid-addition salt thereof.
2. The process according to claim 1 wherein R is hydrogen.
3. The process according to claim 1 wherein R1 is lower alkyl of 1 to 3 carbon atoms.
4. The process according to claim 1 wherein A is (CH2)2 or (CH2)3.
5. The process according to claim 1 wherein B is .
6. The process according to claim 1 wherein A is (CH2)3; and B is N(CH3)2.
7. The process according to claim 1 wherein m is 2.
8. The process according to claim 1 wherein m is 3.
9. The process according to claim 1 wherein m is 4.
10. The process according to claim 1 wherein 2,6-bis(phenylmethylene)cyclohexanone is reacted with 3-dimethylamino-propylhydrazine and the reaction product is treated with oxalic acid to produce 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt.
11. The process according to claim 1 wherein 2,7-bis(phenylmethylene)cycloheptanone is reacted with 3-dimethyl-aminopropylhydrazine and the reaction product is treated with maleic acid to produce 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamine, maleate salt.
12. The process according to claim 1 wherein 2,5-bis(phenylmethylene)cyclopentanone is reacted with 3-diemthylamino-propylhydrazine and the reaction produce is treated with hydrochloric acid to produce 3a,4,5,6-tetrahydro-N,N-dimethyl-3-phenyl-6-(phenylmethylene)cyclopentapyrazole-2(3H)-propanamine, hydro-chloride.
13. The process according to claim 1 wherein 2,6-bis(phenylmethylene)cyclohexanone is reacted with 2-dimethylamino-ethylhydrazine and the reaction product is treated with oxalic acid to produce 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-(2H)-indazole-2-ethanamine, oxalate salt.
14. The process according to claim 1 wherein 2,6-bis(phenylmethylene)cyclohexanone is reacted with 3-diethyl-aminopropylhydrazine and the reaction product is treated with oxalic acid to produce 3,3a,4,5,6,7-hexahydro-N,N-diethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt.
15. A compound of the formula wherein R is hydrogen or lower alkyl with the proviso that only one occurrence of R may be lower alkyl; m is an integer from 2 to 4; A is straight or branched alkylene of from 2 to 5 carbon atoms;
B is -NH2, , wherein R1 is lower alkyl ; or an acid-addition salt thereof, whenever prepared according to the process of claim 1.
B is -NH2, , wherein R1 is lower alkyl ; or an acid-addition salt thereof, whenever prepared according to the process of claim 1.
16. A compound as defined in claim 15 wherein R is hydrogen, whenever prepared according to the process of claim 2.
17. A compound as defined in claim 15 wherein R1 is lower alkyl of 1 to 3 carbon atoms, whenever prepared according to the process of claim 3.
18. A compound as defined in claim 15 wherein A is (CH2)2 or (CH2)3, whenever prepared according to the process of claim 4.
19. A compound as defined in claim 15 wherein B is , whenever prepared according to the process of claim 5.
20. A compound as defined in claim 15 wherein A is (CH2)3; and B is N(CH3)2, whenever prepared according to the process of claim 6.
21. A compound as defined in claim 15 wherein m is 2, whenever prepared according to the process of claim 7.
22. A compound as defined in claim 15 wherein m is 3, whenever prepared according to the process of claim 8.
23. A compound as defined in claim 15 wherein m is 4, whenever prepared according to the process of claim 9.
24. The compound having the name 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt, whenever prepared according to the process of claim 10.
25. The compound having the name 3a,4,5,6,7,8-hexahydro-N,N-dimethyl-3-phenyl-8-(phenylmethylene)-cyclohepta-[c]pyrazole-2(3H)-propanamine, maleate salt, whenever prepared according to the process of claim 11.
26. The compound having the name 3a,4,5,6-tetrahydro-N,N-dimethyl-3-phenyl6-(phenylmethylene)cyclopentapyrazole-2(3H)-propanamine, hydrochloride, whenever prepared according to the process of claim 12.
27. The compound having the name 3,3a,4,5,6,7-hexahydro-N,N-dimethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-ethanamine, oxalate salt, whenever prepared according to the process of claim 13.
28. The compound having the name 3,3a,4,5,6,7-hexahydro-N,N-diethyl-3-phenyl-7-(phenylmethylene)-2H-indazole-2-propanamine, oxalate salt, whenever prepared according to the process of claim 14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46917174A | 1974-05-13 | 1974-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1065324A true CA1065324A (en) | 1979-10-30 |
Family
ID=23862720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA226,132A Expired CA1065324A (en) | 1974-05-13 | 1975-05-02 | 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS50160271A (en) |
| CA (1) | CA1065324A (en) |
| DE (1) | DE2521299A1 (en) |
| FR (1) | FR2270871B1 (en) |
| GB (1) | GB1512653A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004007A (en) * | 1975-08-08 | 1977-01-18 | E. R. Squibb & Sons, Inc. | 2-Heterocyclicalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2H-indazoles |
| ID17907A (en) * | 1997-02-20 | 1998-02-05 | Fakultas Farmasi Uni Gajah Mad | BENZILIDIN CYCYLOHEXANON BENZILIDINE CYCOPOPANANONE BINZYLIDINE ACETONE AND ITS PRODUCTION |
| EP2152695A2 (en) | 2007-06-01 | 2010-02-17 | Schering Corporation | Gamma secretase modulators |
| CA2742472A1 (en) * | 2008-11-13 | 2010-05-20 | Schering Corporation | Gamma secretase modulators |
-
1975
- 1975-05-02 CA CA226,132A patent/CA1065324A/en not_active Expired
- 1975-05-09 GB GB1968275A patent/GB1512653A/en not_active Expired
- 1975-05-13 JP JP5788275A patent/JPS50160271A/ja active Pending
- 1975-05-13 FR FR7514896A patent/FR2270871B1/fr not_active Expired
- 1975-05-13 DE DE19752521299 patent/DE2521299A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPS50160271A (en) | 1975-12-25 |
| FR2270871B1 (en) | 1978-08-04 |
| GB1512653A (en) | 1978-06-01 |
| FR2270871A1 (en) | 1975-12-12 |
| DE2521299A1 (en) | 1975-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880002232B1 (en) | Quinoline derivatives and salts thereof | |
| JPS6051174A (en) | Manufacture of novel arylpiperidine derivative | |
| JPH0647586B2 (en) | 1-Heteroaryl-4-[(2.5-pyrrolidindione-1-yl) alkyl] piperazine derivative | |
| DK155327B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 5H-2,3-BENZODIAZEPINE DERIVATIVES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT | |
| EP0167901A2 (en) | Active compounds | |
| CA1065324A (en) | 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles | |
| CN101855223A (en) | New 1,4-diaza-bicyclo[3.2.2]nonylpyrimidine derivatives and their pharmaceutical applications | |
| PL91712B1 (en) | ||
| PT90127B (en) | A PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC ACTION CONTAINING 4-ARYL-4-PIPERIDINE (OR PYRROLIDINE OR HEXE-HYDROAZEPINE) -CARBINOIS OR ITS HETEROCYCLIC ANALOGS | |
| US4446141A (en) | Hypotensive piperidine derivatives | |
| US3859439A (en) | 2,3-dihydro-5 -trifluoromethyl-1h-dibenzo(2,3:6,7) thiepino (4,5-c) pyrroles as cns-depressants | |
| CN101970438A (en) | New 1,4-diaza-bicyclo[3.2.2]nonylpyrimidine derivatives and their medical applications | |
| KR910002566B1 (en) | 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzooxazonin and -1,4-benzoxazonin compounds, methods for their preparation and pharmaceuticals comprising the same Composition | |
| US3957762A (en) | 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7(phenylmethylene)-2h-indazoles | |
| US4012373A (en) | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones | |
| US4707484A (en) | Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives | |
| US4705807A (en) | Amine derivatives | |
| US4303660A (en) | Pyrazolo[1,5-c]quinazoline derivatives and analgesic compositions containing them | |
| US3960848A (en) | 2-Aminoalkyl-3a,4,5,6,7,8-hexahydro-3-phenyl-8-(phenylmethylene)-cyclopenta[c]pyrazoles | |
| US4160766A (en) | Amino containing benzazepines | |
| US4085102A (en) | 2-Amino-8-arylideno-3,4,5,6,7,8-hexahydro-4-arlypyrido[4,3-d]pyrimidines | |
| KR880001298B1 (en) | Preparation of benzoyl-phenyl-piperidine derivatives | |
| US4033970A (en) | Various 1,5,10,11-tetrahydrobenzo [4,5]-cyclohepta [1,2-b]pyrazolo[4,3-e]pyridine derivatives | |
| JPH0448792B2 (en) | ||
| US4146624A (en) | Method of treating viruses with bis-basic ketones of dibenzofuran |